Cover Image
市場調查報告書

CD19療法市場:2016-2030年

CD19 Therapeutics Market, 2016 - 2030

出版商 ROOTS ANALYSIS 商品編碼 356140
出版日期 內容資訊 英文 302 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
CD19療法市場:2016-2030年 CD19 Therapeutics Market, 2016 - 2030
出版日期: 2016年03月31日 內容資訊: 英文 302 Pages
簡介

本報告提供抗CD-19療法擴大的開發平台的目前市場情形、未來展望相關整體分析,對於主要企業、開發中產品的開發階段、標的疾病的現狀,技術平台、產品共同開發、共同商品化相關聯盟、許可證協定情形,競爭情形短期、長期性的成長來說的威脅,目標顧客區隔為基礎的開發、銷售的可能性等系統性資訊。

第1章 序文

第2章 摘要整理

第3章 簡介

  • 本章概要
  • CD19抗原
  • 癌症的治療:關心的高漲
  • 抗體為基礎的療法
  • CD19為基礎的療法:新領域

第4章 市場概要

  • 本章概要
  • CD19療法:有前途的開發平台
  • 開發平台分析
  • CD19療法:合作

第5章 嵌合抗原受體:T細胞療法

  • 本章概要
  • 簡介
  • 發展歷史
  • 目前研究情形
  • 嵌合抗原受體的解剖學的設計
  • 嵌合抗原受體的世代
  • CAR-T細胞的開發
  • 毒性的問題
  • 毒性問題的經營管理
  • CAR-T療法相關課題
  • 以CD19為標的之CAR-T分子

第6章 改變抗體

  • 本章概要
  • 單株抗體
  • 改變抗體的優點
  • 以CD19為標的之改變抗體
  • CD19為基礎的改變抗體的開發所採用的技術

第7章 雙特異性抗體

  • 本章概要
  • 雙特異性抗體
  • 雙特異性的優點
  • 雙特異性抗體的格式
  • 雙特異性抗體的發展
  • 雙特異性抗體的種類:各作用機制
  • 以CD19為目標的雙特異性抗體
  • CD19為基礎的雙特異性抗體的開發所採用的技術

第8章 抗體藥物複合體 (ADC)

  • 本章概要
  • 發展歷史
  • ADC的必需零組件
  • 作用機制
  • 把CD19為目標的抗體藥物複合體 (ADC)

第9章 主要治療領域

  • 情境、背景
  • 白血病
  • 淋巴瘤
  • 白血病、淋巴瘤的目前治療形勢
  • 自體免疫疾病:抗CD-19醫藥品的潛在領域

第10章 市場預測

  • 本章概要
  • 調查範圍、限制
  • 預測手法
  • 整體CD19治療藥市場
  • BLINCYTO (Amgen)
  • CTL019 (Novartis)
  • KTE-C19 (Kite Pharma)
  • JCAR015 (Juno Therapeutics)
  • Coltuximab Ravtansine (Immunogen)
  • MEDI-551 (MedImmune)
  • MOR208 (Morphosys)
  • XMAB 5871 (Xencor)
  • SGN-CD19A (Seattle Genetics)

第11章 結論

第12章 採訪

附錄I:圖表資料

附錄II:企業清單

圖表

目錄
Product Code: RA10057

The human immune system is comprised of a number of different types of specialized molecules and cells that are involved in complex interactions and activities to facilitate an immune response. Immunotherapies exploit the body's innate potential to specifically target a particular molecular antigen and mount an efficient immune response against the cells bearing the diseased signature. Currently, four major types of immunotherapies (classified by product class) targeting the CD19 antigen are under development, namely engineered antibodies, bispecific antibodies (bsAbs), antibody drug conjugates (ADCs) and CAR-T cell therapies. CD19 antigen, an important biomarker has emerged as a promising therapeutic target for a number of disease indications, specifically hematological malignancies (leukemias and lymphomas). The antigen is expressed both on normal cells and malignant B cells as well as follicular dendritic cells. Upon initial discovery, the CD19 antigen was dubbed as the B4 antigen on human B cells.

The pioneer CD19 targeted drug to hit the US and the EU markets was BLINCYTO® (blinatumomab), a bsAb. Different technologies have catered to the development of CD19 targeted therapies. Several researchers and therapy developers are actively involved in developing therapeutics targeting the CD19 antigen for the treatment of B cell malignancies and various autoimmune disorders. With several advantages such as high therapeutic performance and favorable clinical outcomes, the promising pipeline of anti-CD19 drugs is expected to result in a multi-billion dollar market by 2030.

Synopsis

The 'CD19 Therapeutics Market, 2016-2030' report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of anti-CD19 therapeutics. The recent approval of BLINCYTO®, a CD19 targeting bsAb, and emergence of CAR-T therapies has provided a significant boost to this market that has actively evolved in the past few years.

The pipeline comprises of products across four major classes of drugs, namely, engineered antibodies, bsAbs, ADCs and CAR-T therapies. The major focus of these novel molecules is hematological cancers, specifically B cell malignancies, with CAR-T therapies leading the table. Post initial research in CAR-T therapies, many non-industry players have entered into collaborations with industry stakeholders to fund the clinical and commercial development of these products. Some late stage products that have emerged out of such collaborations include KTE-C19, CTL019, JCAR015 and JCAR017.

One of the key objectives of the study is to review and quantify the opportunities laid by the innovative CD19 targeted programs of both small and big pharma firms. Amongst other elements, the report elaborates upon the following key areas:

  • The current state of the market with respect to key players, developmental stages of pipeline products (both clinical/preclinical) and target indications
  • Partnerships that have taken place in the recent past covering research and development collaborations, manufacturing agreements and license agreements specific to technology platforms, product co-development and co-commercialization
  • Competitive landscape and inherent threats to growth in the short and long term
  • Development and sales potential based on target consumer segments, likely adoption rate and expected pricing

The study provides an estimate of the short-mid term and long term market forecast for the period 2015 - 2030. The research, analysis and insights presented in this report include potential sales of various marketed and late stage (phase II and phase II/III) anti-CD19 products based on our understanding of the likely future development of individual therapeutics. The opinions and insights, presented in this study, were influenced by discussions that we conducted with experts in this area. These included senior representatives at Kite Pharma, MorphoSys and Theravectys.

Owing to niche nature of the market, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. All actual figures have been sourced and analyzed from publicly available information and discussions with industry experts. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1. CD19 is an important antigen expressed during B cell development; 80% of all ALL cases, 88% of B cell lymphomas and 100% of B cell leukemias express this antigen.
  • 2. During the course of our research, we identified over 50 products in various phases of development. Of these, 70% are in the clinical phase of development (with one molecule in phase II/III trial and six molecules in phase II stage).
  • 3. CAR-T therapies (constituting 70% of the development pipeline) are the most common, followed by bsAbs (11%), ADCs (7%) and engineered antibodies (7%).
  • 4. The market is highly fragmented with the involvement of several start-ups and many eminent research organizations. Big pharmaceutical players engaged in this space include Amgen, ImmunoGen, MedImmune, Merck and Novartis. Emerging new players/start-ups that are actively investing in this market include Affimed, Bellicum Pharmaceuticals, Juno Therapeutics, Kite Pharma, MorphoSys, Xencor and Zymeworks. The premier research institutes involved in this space include the National Cancer Institute (NCI), MD Anderson Cancer Centre, the University of Pennsylvania, Fred Hutchinson Cancer Research Center (FHCRC) and Memorial Sloan Kettering Cancer Center (MSKCC).
  • 5. Hematological malignancies remain the prime focus of drug developers in this space. However, efforts are also being made to use these therapies in the treatment of other indications including certain autoimmune diseases and solid tumors.
  • 6. Over the coming decade, we expect at least eight anti-CD19 therapies to be made commercially available in addition to marketed drugs. During this period, we believe the market is likely to expand at an annualized growth rate of 41.0%; the overall opportunity could be much higher and depends on a number of factors such as favourable market environment, regulatory regimes and therapeutic performance of candidates in the late stages of development.

Research Methodology

Most of the data presented in this report has been gathered via secondary research. For all our projects, we also conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information. The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various sources of information.

Chapter Outlines

Chapter 2 presents an executive summary of the report. It offers a high level view on where the CD19 therapeutics market is headed in the mid-long term.

Chapter 3 provides a detailed introduction to the CD19 antigen. In this section, we have talked about the structure and role of the human CD19 antigen. Further, we have briefly discussed the conventional therapies being used for different oncological indications and the advent of cancer immunotherapy.

Chapter 4 includes information on over 50 molecules that are either approved or in different stages of development (both clinical and preclinical/discovery). The detailed analysis of this development pipeline includes information on types of molecules, most commonly targeted indications, the phase of development and the developers. In addition, we have also highlighted specific details on the different types of partnerships that have been inked over the last few years; this showcases the growing interest in this field.

Chapter 5 focuses on CAR-T based therapies and highlights prevailing trends pertaining to the ongoing research in this field. It features discussions on targets under investigation, current challenges, toxicity issues and other relevant parameters. To credit the work of the eminent researchers in this space, we have mapped the regional locations of prominent key opinion leaders (KOLs). Similar to earlier chapters, this chapter provides detailed technology and drug profiles for CD19 targeting late stage CAR-T molecules.

Chapter 6 provides detailed information on engineered antibodies, namely Fc and glycoengineered antibodies. It also covers detailed drug profiles for late stage molecules that specifically target the CD19 antigen. Each drug profile includes information such as the clinical stage of development of the molecule, dosage regimen, key clinical trial results and information about the developer. The chapter also includes profiles of technologies being used for the development of these candidate therapies. These profiles provide a brief technology background, pipeline molecules based on the particular technology platform, specific advantages and recent collaborations.

Chapter 7 provides detailed information on bsAbs. Similar to the previous chapter, it provides both drug and technology profiles for CD19 targeting bsAb therapeutics in late stages of clinical development.

Chapter 8 provides detailed information on ADCs. Similar to the previous chapters, it provides both drug and technology profiles for CD19 targeting ADC therapeutics in late stages of clinical development.

Chapter 9 highlights promising therapeutic areas for which CD19 therapeutics are being developed. The chapter also highlights the epidemiological facts and currently available treatment options for each of the discussed indications.

Chapter 10 elaborates on the monetary opportunity presented by anti-CD19 therapeutics. It provides a comprehensive market forecast analysis for molecules in advanced stages of development (approved, phase II/III, phase II and phase I/II) taking into consideration the target patient population, competition, likely adoption rate and price points.

Chapter 11 is an overall summary of the report. In this chapter, we have provided a list of key takeaways and expressed our independent opinion based on the research and analysis described in earlier chapters.

Chapter 12 is a collection of transcripts of interviews conducted during the course of the study.

Chapter 13 is an appendix, containing tabulated data for all figures in the report. It also features a list of companies and organizations involved in this space.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. The CD19 Antigen
    • 3.2.1. Overview
    • 3.2.2. Structure of the Human CD19 Antigen
    • 3.2.3. Role of the CD19 Antigen
      • 3.2.3.1. Development and Maturation of B cells
      • 3.2.3.2. Role in B cell Signaling
    • 3.2.4. CD19: A Promising Antigen
  • 3.3. Treating Cancer: A Growing Concern
    • 3.3.1. Evolution of Cancer Treatment
    • 3.3.2. Conventional Cancer Treatment Methods
      • 3.3.2.1. Surgery
      • 3.3.2.2. Radiation Therapy
      • 3.3.2.3. Chemotherapy
    • 3.3.3. Immunotherapy
      • 3.3.3.1. Classification of Cancer Immunotherapies
        • 3.3.3.1.1. By Mechanism of Action
        • 3.3.3.1.2. By Type of Target
        • 3.3.3.1.3. By Approach
        • 3.3.3.1.4. By Product Class
          • 3.3.3.1.4.1. Monoclonal Antibodies
          • 3.3.3.1.4.2. Bispecific Antibodies
          • 3.3.3.1.4.3. Antibody Drug Conjugates
          • 3.3.3.1.4.4. Chimeric Antigen Receptor-T Cells
  • 3.4. Antibody Based Therapeutics
    • 3.4.1. Approved Antibody Therapies: Distribution by Year of Approval
  • 3.5. CD19 Based Therapeutics: New Frontiers

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. CD19 Therapeutics: A Promising Pipeline
  • 4.3. Pipeline Analysis
    • 4.3.1. CD19 Therapeutics: Distribution by Phase of Development
    • 4.3.2. CD19 Therapeutics: Distribution by Indication
    • 4.3.3. CD19 Therapeutics: Distribution by Type of Molecule
    • 4.3.4. CD19 Therapeutics: Distribution by Type of Developer
    • 4.3.5. Active Players in the CD19 Therapeutics Industry
  • 4.4. CD19 Therapeutics: Collaborations

5. CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPIES

  • 5.1. Chapter Overview
  • 5.2. Introduction
  • 5.3. History of Development
  • 5.4. Current Research Landscape
  • 5.5. Anatomical Layout of Chimeric Antigen Receptor
  • 5.6. Generations of Chimeric Antigen Receptors
  • 5.7. Development of Car-T Cells
  • 5.8. Toxicity Issues
    • 5.8.1. Cytokine Release Syndrome (CRS)
    • 5.8.2. On-Target Off-Tumor Toxicity
    • 5.8.3. Encephalopathy and B Cell Aplasia
  • 5.9. Management of Toxicity Issues
    • 5.9.1. Target Selection
    • 5.9.2. Cell Persistence
    • 5.9.3. Receptor Expression
  • 5.10. Challenges Associated With CAR-T Therapy
    • 5.10.1. Competitive Risks
    • 5.10.2. Clinical Risks
    • 5.10.3. Regulatory Challenges
    • 5.10.4. Commercial Risks
  • 5.11. CAR-T Molecules Targeting CD19
    • 5.11.1. CTL019, Novartis
      • 5.11.1.1. Introduction
      • 5.11.1.2. History of Development
      • 5.11.1.3. Clinical Development
      • 5.11.1.4. Dosage Regimen
      • 5.11.1.5. Key Clinical Trial Results
        • 5.11.1.5.1. Acute Lymphoblastic Leukemia
        • 5.11.1.5.2. Non Hodgkin Lymphoma
        • 5.11.1.5.3. Chronic Lymphocytic Leukemia
        • 5.11.1.5.4. Multiple Myeloma
      • 5.11.1.6. Developer Overview: Novartis
        • 5.11.1.6.1. Financial Information
        • 5.11.1.6.2. Product Portfolio
        • 5.11.1.6.3. Patent Litigation
        • 5.11.1.6.4. Manufacturing Capabilities
      • 5.11.1.7. Collaborations
    • 5.11.2. JCAR015, Juno Therapeutics
      • 5.11.2.1. Drug Overview
      • 5.11.2.2. CAR-T Design
      • 5.11.2.3. Clinical Development
      • 5.11.2.4. Dosage Regimen
      • 5.11.2.5. Key Clinical Trial Results
        • 5.11.2.5.1. Acute Lymphoblastic Leukemia
        • 5.11.2.5.2. Non-Hodgkin Lymphoma
      • 5.11.2.6. Developer Overview: Juno Therapeutics
        • 5.11.2.6.1. Financial Information
        • 5.11.2.6.2. Product Portfolio
        • 5.11.2.6.3. Patent Litigation
        • 5.11.2.6.4. Manufacturing Capabilities
      • 5.11.2.7. Collaborations
    • 5.11.3. KTE-C19, Kite Pharma
      • 5.11.3.1. Introduction
      • 5.11.3.2. Clinical Development
      • 5.11.3.3. Dosage Regimen
      • 5.11.3.4. Key Clinical Trial Results
        • 5.11.3.4.1. Non-Hodgkin Lymphoma
        • 5.11.3.4.2. Acute Lymphoblastic Leukemia
      • 5.11.3.5. Next Generation eACT CAR Candidates
      • 5.11.3.6. Developer Overview: Kite Pharma
        • 5.11.3.6.1. Financial Information
        • 5.11.3.6.2. Product Portfolio
        • 5.11.3.6.3. Manufacturing Capabilities
      • 5.11.3.7. Collaborations

6. ENGINEERED ANTIBODIES

  • 6.1. Chapter Overview
  • 6.2. Monoclonal Antibody
    • 6.2.1. How Monoclonal Antibody Therapy Works?
    • 6.2.2. Parts of a Monoclonal Antibody
    • 6.2.3. Fc Region and Effector Functions
    • 6.2.4. Types of Fc Receptors
    • 6.2.5. Engineering the Fc Region
      • 6.2.5.1. Glycoengineering
      • 6.2.5.2. Protein Engineering
      • 6.2.5.3. Isotype Chimerism
  • 6.3. Advantages of Engineered Antibodies
  • 6.4. Engineered Antibodies Targeting CD19
    • 6.4.1. MEDI-551, MedImmune
      • 6.4.1.1. Drug Overview
      • 6.4.1.2. Clinical Development
      • 6.4.1.3. Dosage Regimen
      • 6.4.1.4. Key Clinical Trial Results
        • 6.4.1.4.1. Chronic Lymphocytic Leukemia
        • 6.4.1.4.2. B Cell Malignancies
        • 6.4.1.4.3. Multiple Sclerosis
        • 6.4.1.4.4. Scleroderma
      • 6.4.1.5. Developer Overview: MedImmune
        • 6.4.1.5.1. Product Portfolio
        • 6.4.1.5.2. Manufacturing Capabilities
      • 6.4.1.6. Collaborations
    • 6.4.2. MOR208, MorphoSys
      • 6.4.2.1. Drug Overview
      • 6.4.2.2. History of Development
      • 6.4.2.3. Clinical Development
      • 6.4.2.4. Dosage Regimen
      • 6.4.2.5. Key Clinical Trial Results
        • 6.4.2.5.1. Non-Hodgkin Lymphoma
        • 6.4.2.5.2. Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
      • 6.4.2.6. Developer Overview: MorphoSys
        • 6.4.2.6.1. Financial Information
        • 6.4.2.6.2. Product Portfolio
      • 6.4.2.7. Collaborations
  • 6.5. Technologies Used For Developing Cd19 Based Engineered Antibodies
    • 6.5.1. POTELLIGENT®, BioWa (A Subsidiary of Kyowa Hakko Kirin)
      • 6.5.1.1. The Technology
      • 6.5.1.2. Discovery of POTELLIGENT®
      • 6.5.1.3. Advantages of POTELLIGENT® Technology
      • 6.5.1.4. POTELLIGENT® CHOK1SV: A 2-in-1 Technology
      • 6.5.1.5. Drugs Based on POTELLIGENT®
      • 6.5.1.6. Technology Licensees
        • 6.5.1.6.1. Cantargia
        • 6.5.1.6.2. arGEN-X
        • 6.5.1.6.3. MedImmune
        • 6.5.1.6.4. Pfizer
        • 6.5.1.6.5. FivePrime Therapeutics
        • 6.5.1.6.6. ImmunoCellular Therapeutics
        • 6.5.1.6.7. Oxford BioTherapeutics
        • 6.5.1.6.8. Kalobios
        • 6.5.1.6.9. Agensys
        • 6.5.1.6.10. Daiichi Sankyo
        • 6.5.1.6.11. GSK
        • 6.5.1.6.12. NKT Therapeutics
        • 6.5.1.6.13. Otsuka Pharmaceuticals
        • 6.5.1.6.14. Merck KGaA
        • 6.5.1.6.15. Sanofi Aventis
        • 6.5.1.6.16. CSL Limited
        • 6.5.1.6.17. Novartis
        • 6.5.1.6.18. Genentech
        • 6.5.1.6.19. Takeda
        • 6.5.1.6.20. UCB
        • 6.5.1.6.21. OncoTherapy Science
        • 6.5.1.6.22. Medarex (Acquired by BMS)
      • 6.5.1.7. Product Alliances
        • 6.5.1.7.1. Amgen
        • 6.5.1.7.2. Teva Pharmaceuticals
        • 6.5.1.7.3. MedImmune
    • 6.5.2. XmAb® Antibody Technology, Xencor
      • 6.5.2.1. The Technology
      • 6.5.2.2. Drugs Based on XmAb® Antibody Technology
      • 6.5.2.3. Technology Licensees
        • 6.5.2.3.1. Amgen
        • 6.5.2.3.2. Novo Nordisk
        • 6.5.2.3.3. Merck (MSD outside the US and Canada)
        • 6.5.2.3.4. CSL Limited
        • 6.5.2.3.5. Janssen (Formerly Centocor Research & Development)
        • 6.5.2.3.6. Merck & Co
        • 6.5.2.3.7. Pfizer
        • 6.5.2.3.8. Human Genome Sciences (HGS)
        • 6.5.2.3.9. Boehringer Ingelheim
      • 6.5.2.4. Product Alliances
        • 6.5.2.4.1. Amgen
        • 6.5.2.4.2. MorphoSys

7. BISPECIFIC ANTIBODIES

  • 7.1. Chapter Overview
  • 7.2. Bispecific Antibody
  • 7.3. The Bispecific Advantage
  • 7.4. Bispecific Antibody Formats
  • 7.5. Evolution of Bispecific Antibodies
    • 7.5.1. First Generation Bispecific Antibodies
      • 7.5.1.1. Triomabs: Made Using Hybridomas/Quadromas
      • 7.5.1.2. Shortcomings of First Generation Bispecific Antibodies
    • 7.5.2. Second Generation Bispecific Antibodies
      • 7.5.2.1. Tandem Single-chain Variable Fragment (ScFv)
      • 7.5.2.2. Diabodies
      • 7.5.2.3. Two-in-one Antibody
      • 7.5.2.4. Dual Variable Domain Antibodies (DVD-Ig)
      • 7.5.2.5. Shortcoming of Recombinant Bispecific Antibodies
  • 7.6. Types of Bispecific Antibodies by Mode of Action
    • 7.6.1. T Cell Engagement
    • 7.6.2. Pre-Targeting Systems
    • 7.6.3. Ligand Neutralization and Cross Linking of Receptors System
  • 7.7. Bispecific Antibodies Targeting CD19
    • 7.7.1. Blincyto® (Blinatumomab/Mt 103/Medi 538/Amg 103), Amgen/Astellas Pharma
      • 7.7.1.1. Drug Overview
      • 7.7.1.2. History of Development
      • 7.7.1.3. Mechanism of Action
      • 7.7.1.4. Clinical Development
      • 7.7.1.5. Dosing Regimen
      • 7.7.1.6. Key Clinical Trial Results
        • 7.7.1.6.1. Philadelphia Chromosome-Negative B Cell Precursor ALL
        • 7.7.1.6.2. Philadelphia Chromosome-Positive B Cell Precursor ALL
        • 7.7.1.6.3. Minimal Residual Disease of Acute Lymphoblastic Leukemia
        • 7.7.1.6.4. Relapsed/Refractory Acute Lymphoblastic Leukemia
        • 7.7.1.6.5. Diffuse Large B Cell Lymphoma
        • 7.7.1.6.6. Non-Hodgkin Lymphoma
      • 7.7.1.7. Developer Overview: Amgen
        • 7.7.1.7.1. Financial Performance
        • 7.7.1.7.2. Product Portfolio
      • 7.7.1.8. Collaborations
  • 7.8. Technologies Used For Developing CD19 Based Bispecific Antibodies
    • 7.8.1. Bispecific T Cell Engager (BiTE®), Amgen
      • 7.8.1.1. The Technology
      • 7.8.1.2. Advantages of BiTE® Technology
      • 7.8.1.3. Drugs Based on BiTE® Technology
      • 7.8.1.4. Technology Licensees
        • 7.8.1.4.1. MD Anderson Cancer Center (University of Texas)
        • 7.8.1.4.2. Boehringer Ingelheim
        • 7.8.1.4.3. Bayer Healthcare (previously Bayer Schering Pharma)
        • 7.8.1.4.4. Sanofi Aventis
      • 7.8.1.5. Product Alliances
        • 7.8.1.5.1. MedImmune
    • 7.8.2. Dual-Affinity Re-Targeting (DART®), MacroGenics
      • 7.8.2.1. The Technology
      • 7.8.2.2. Advantages of DART® Technology
      • 7.8.2.3. Drugs Based on DART® Technology
      • 7.8.2.4. Technology Licensees
        • 7.8.2.4.1. Boehringer Ingelheim
        • 7.8.2.4.2. Pfizer
      • 7.8.2.5. Product Alliances
        • 7.8.2.5.1. NIAID
        • 7.8.2.5.2. Janssen
        • 7.8.2.5.3. Takeda
        • 7.8.2.5.4. Gilead Sciences
        • 7.8.2.5.5. Servier
    • 7.8.3. TandAb, Affimed
      • 7.8.3.1. The Technology
      • 7.8.3.2. Advantages of TandAb Technology
      • 7.8.3.3. Drugs Based on TandAb Technology
      • 7.8.3.4. Technology Licensees

8. ANTIBODY DRUG CONJUGATES (ADCs)

  • 8.1. Chapter Overview
  • 8.2. History of Development
  • 8.3. Essential Components of ADCs
    • 8.3.1. Antibody
    • 8.3.2. Cytotoxin
    • 8.3.3. Linker
  • 8.4. Mechanism of Action
  • 8.5. Antibody Drug Conjugates Targeting CD19
    • 8.5.1. Coltuximab Ravtansine (formerly SAR3419), ImmunoGen
      • 8.5.1.1. Drug Overview
      • 8.5.1.2. History of Development
      • 8.5.1.3. Mechanism of Action
      • 8.5.1.4. Clinical Development
      • 8.5.1.5. Dosage Regimen
      • 8.5.1.6. Key Clinical Trial Results
        • 8.5.1.6.1. Diffuse Large B Cell Lymphoma
        • 8.5.1.6.2. Non-Hodgkin Lymphoma
      • 8.5.1.7. Developer Overview: ImmunoGen
        • 8.5.1.7.1. Financial Performance
        • 8.5.1.7.2. Product Portfolio
        • 8.5.1.7.3. Technology Portfolio
      • 8.5.1.8. Collaborations
    • 8.5.2. Denintuzumab Mafodotin (SGN-CD19A), Seattle Genetics
      • 8.5.2.1. Drug Overview
      • 8.5.2.2. Mechanism of Action
      • 8.5.2.3. Clinical Development
      • 8.5.2.4. Dosage Regimen
      • 8.5.2.5. Key Clinical Trial Results
        • 8.5.2.5.1. Non-Hodgkin Lymphoma
        • 8.5.2.5.2. Acute Lymphocytic Leukemia
      • 8.5.2.6. Developer Overview: Seattle Genetics
        • 8.5.2.6.1. Financial Performance
        • 8.5.2.6.2. Product Portfolio
        • 8.5.2.6.3. Technology Platform

9. KEY THERAPEUTIC AREAS

  • 9.1. Context and Background
  • 9.2. Leukemia
    • 9.2.1. Introduction and Epidemiology
      • 9.2.1.1. Acute Myeloid Leukemia
      • 9.2.1.2. Chronic Myeloid Leukemia
      • 9.2.1.3. Acute Lymphocytic Leukemia
      • 9.2.1.4. Chronic Lymphocytic Leukemia
  • 9.3. Lymphoma
    • 9.3.1. Introduction and Epidemiology
  • 9.4. Current Treatment Landscape for Leukemia and Lymphoma
    • 9.4.1. Targeted Therapies
    • 9.4.2. CD19 Therapies and Research Landscape for Treatment of Leukemia/Lymphoma
      • 9.4.2.1. CD19 Based Engineered Antibodies
      • 9.4.2.2. CD19 Based Bispecific Antibodies
      • 9.4.2.3. CD19 Based Antibody Drug Conjugates
      • 9.4.2.4. CD19 Based Chimeric Antigen Receptor T Cells
  • 9.5. Autoimmune Disorders: A Potential Area for Anti-CD19 Drugs

10. MARKET FORECAST

  • 10.1. Chapter Overview
  • 10.2. Scope and Limitations
  • 10.3. Forecast Methodology
  • 10.4. Overall CD19 Therapeutics Market
  • 10.5. BLINCYTO® (Amgen)
    • 10.5.1. Target Patient Population
    • 10.5.2. Sales Forecast
  • 10.6. CTL019 (Novartis)
    • 10.6.1. Target Patient Population
    • 10.6.2. Sales Forecast
  • 10.7. KTE-C19 (Kite Pharma)
    • 10.7.1. Target Patient Population
    • 10.7.2. Sales Forecast
  • 10.8. JCAR015 (Juno Therapeutics)
    • 10.8.1. Target Patient Population
    • 10.8.2. Sales Forecast
  • 10.9. Coltuximab Ravtansine (Immunogen)
    • 10.9.1. Target Patient Population
    • 10.9.2. Sales Forecast
  • 10.10. MEDI-551 (MedImmune)
    • 10.10.1. Target Patient Population
    • 10.10.2. Sales Forecast
  • 10.11. MOR208 (Morphosys)
    • 10.11.1. Target Patient Population
    • 10.11.2. Sales Forecast
  • 10.12. XMAB®5871 (Xencor)
    • 10.12.1. Target Patient Population
    • 10.12.2. Sales Forecast
  • 10.13 SGN-CD19A (Seattle Genetics)
    • 10.13.1. Target Patient Population
    • 10.13.2. Sales Forecast

11. CONCLUSION

  • 11.1. CD19: Potential Antigen for Targeted Therapy
  • 11.2. Hematological Malignancies: The Main Focus Area
  • 11.3. Immunotherapy: The Fourth Major Pillar of Cancer Therapy
  • 11.4. CAR-T Therapies: The Current Flag-Bearer
  • 11.5. Market Landscape: An Amalgamation of Industry and Non-Industry Participants
  • 11.6. Advanced Stage Molecules Expected to Result in a Multi-Billion Dollar Market

12. INTERVIEW TRANSCRIPTS

  • 12.1. Chapter Overview
  • 12.2. Adrian Bot, Vice President, Translational Sciences, Kite Pharma
  • 12.3. Dr. Andrea Gnirke-Maier, Senior Business Analyst, Business Development, Morphosys
  • 12.4. Aino Kalervo, Competitive Intelligence Manager - Strategy & Business Development, Theravectys

APPENDIX 1: TABULATED DATA

APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Lisrt of Figures

  • Figure 3.1 Structure of Human CD19 Antigen
  • Figure 3.2 Advantages of CD19 Antigen
  • Figure 3.3 Timeline of Cancer Treatments
  • Figure 3.4 Cancer Treatment: Type of Surgeries
  • Figure 3.5 Cancer Treatment: Type of Radiation Therapies
  • Figure 3.6 Cancer Treatment: Type of Chemotherapies
  • Figure 3.7 Cancer Immunotherapy: Active v/s Passive
  • Figure 3.8 Cancer Immunotherapy: Specific vs. Non-Specific
  • Figure 3.9 Approved Antibody Therapies: Distribution by Year of Approval
  • Figure 4.1 CD19 Therapeutics Pipeline: Distribution by Phase of Development (Clinical/Preclinical)
  • Figure 4.2 CD19 Therapeutics Pipeline: Distribution by Phase of Development (Marketed/Phase III/Phase II/Phase I/Preclinical)
  • Figure 4.3 CD19 Therapeutics Pipeline: Distribution by Indication
  • Figure 4.4 CD19 Therapeutics Pipeline: Distribution by Type of NHL
  • Figure 4.5 CD19 Therapeutics Pipeline: Distribution by Type of Molecule
  • Figure 4.6 CD19 Therapeutics Pipeline: Distribution by Type of Developer
  • Figure 4.7 CD19 Therapeutics Pipeline: Active Industry Players
  • Figure 5.1 Historical Timeline: Development of CAR-T Cells
  • Figure 5.2 CAR-T: Mapping Prominent Researchers
  • Figure 5.3 Development of CAR-T Cells
  • Figure 5.4 Challenges in CAR-T Therapy
  • Figure 5.5 CTL019: Clinical Trial Design (Industry)
  • Figure 5.6 CTL019: Clinical Trial Design (Non-Industry)
  • Figure 5.7 Novartis: Revenue, 2010- 2015 (USD Billion)
  • Figure 5.8 Novartis: Sales by Operating Segments, 2015 (USD Billion)
  • Figure 5.10 Juno Therapeutics: VC Funding Instances (USD Million)
  • Figure 5.11 KTE-C19: Clinical Trial Design (Non-Industry)
  • Figure 5.12 KTE-C19: Clinical Trial Design (Industry)
  • Figure 5.13 Kite Pharma: VC Funding Instances (USD Million)
  • Figure 5.14 Manufacturing of CD19 CAR-T Cells: Process Comparison
  • Figure 6.1 Structure of Antibody
  • Figure 6.2 MEDI-551: Clinical Trial Design
  • Figure 6.3 MOR208: Clinical Trial Design
  • Figure 6.4 MorphoSys: Revenue, 2011- Q3, 2015 (EUR Million)
  • Figure 7.1 Blinatumomab: Clinical Trial Design (Industry)
  • Figure 7.2 Blinatumomab: Clinical Trial Design (Non-Industry)
  • Figure 7.3 Amgen: Revenues, 2010 - 2015 (USD Billion)
  • Figure 8.1 Historical Development of ADCs
  • Figure 8.2 Components of ADCs
  • Figure 8.3 Mechanism of Action of ADCs
  • Figure 8.4 Coltuximab Ravtansine: Clinical Trial Design
  • Figure 8.5 ImmunoGen: Revenues, 2011 - H1 2016 (USD Million)
  • Figure 8.6 Denintuzumab Mafodotin: Clinical Trial Design
  • Figure 8.7 Seattle Genetics: Revenues, 2010- 9M, 2015 (USD Million)
  • Figure 9.1 Most Common Types of Leukemia
  • Figure 9.2 Leukemia: Global Epidemiological Distribution
  • Figure 9.3 Lymphoma: Global Epidemiological Distribution
  • Figure 10.1 Overall CD19 Based Therapeutics Market (USD Billion), 2016-2030
  • Figure 10.2 Evolution of CD19 Based Therapeutics Market: 2020, 2025 and 2030 (Base Scenario, USD Billion)
  • Figure 10.3 BLINCYTO®: Current Status by Highest Phase of Development
  • Figure 10.4 BLINCYTO®: Sales Forecast, 2016-2030: Base Scenario (USD Million)
  • Figure 10.5 CTL019: Current Status by Highest Phase of Development
  • Figure 10.6 CTL019 Sales Forecast, 2017-2030: Base Scenario (USD Million)
  • Figure 10.7 KTE-C19: Current Status by Highest Phase of Development
  • Figure 10.8 KTE-C19 Sales Forecast, 2018-2030: Base Scenario (USD Million)
  • Figure 10.9 JCAR015: Current Status by Highest Phase of Development
  • Figure 10.10 JCAR015 Sales Forecast, 2018-2030: Base Scenario (USD Million)
  • Figure 10.11 Coltuximab Ravtansine: Sales Forecast, 2019-2030: Base Scenario (USD Million)
  • Figure 10.12 MEDI-551: Current Status by Highest Phase of Development
  • Figure 10.13 MEDI-551: Sales Forecast, 2020-2030: Base Scenario (USD Million)
  • Figure 10.14 MOR208: Current Status by Highest Phase of Development
  • Figure 10.15 MOR208: Sales Forecast, 2020-2030: Base Scenario (USD Million)
  • Figure 10.16 XmAb®5871: Current Status by Highest Phase of Development
  • Figure 10.17 XmAb®5871: Sales Forecast, 2021-2030: Base Scenario (USD Million)
  • Figure 10.18 SGN-CD19A: Current Status by Highest Phase of Development
  • Figure 10.19 SGN-CD19A: Sales Forecast, 2024-2030: Base Scenario (USD Million)
  • Figure 11.1 CD19 Therapeutics: Distribution by Hematological Malignancies
  • Figure 11.2 CD19 Therapeutics: Market Opportunity Among Different Class of Therapeutics
  • Figure 11.3 CD19 Therapeutics: Market Landscape
  • Figure 11.4 CD19 Therapeutics Market Forecast: Conservative, Base and Optimistic Scenarios, 2016-2030 (USD Billion)

Lisrt of Tables

  • Table 3.1 List of Approved Antibody Therapies
  • Table 4.1 CD19 Therapeutics: Pipeline Molecules
  • Table 4.2 CD19 Therapeutics: Collaborations
  • Table 5.1 Key Characteristics of CAR-T Cells
  • Table 5.2 Comparison between 1st and 2nd Generation CARs
  • Table 5.3 CD19 CAR-T Cells: Preclinical Results
  • Table 5.4 Grading Criteria for CRS
  • Table 5.5 Safety Switches under Development for CAR-T Therapy
  • Table 5.6 CD19 Targeted CAR-T: Pipeline Molecules and Current Status of Development
  • Table 5.7 CTL019: Clinical Development
  • Table 5.8 CTL019: Clinical Trial Endpoints (Adult Studies (Leukemia))
  • Table 5.9 CTL019: Clinical Trial Endpoints (Pediatric Studies)
  • Table 5.10 CTL019: Clinical Trial Endpoints (Adult Studies (Lymphoma & Multiple Myeloma))
  • Table 5.11 Novartis: T Cell Immunotherapy Pipeline
  • Table 5.12 JCAR015: Clinical Development
  • Table 5.13 JCAR015: Clinical Trial Endpoint
  • Table 5.14 JCAR015: Dosage Regimen
  • Table 5.15 Juno Therapeutics: T Cell Immunotherapy Pipeline
  • Table 5.16 KTE-C19: Clinical Development
  • Table 5.17 KTE-C19: Clinical Trial Endpoint (Lymphoma)
  • Table 5.18 KTE-C19: Clinical Trial Endpoint (Leukemia)
  • Table 5.19 Kite Pharma: CAR-T Pipeline
  • Table 6.1 Features of Engineered Fc Regions
  • Table 6.2 CD19 Targeted Engineered Antibodies: Pipeline Molecules and Current Status of Development
  • Table 6.3 MEDI-551: Clinical Trials
  • Table 6.4 MEDI-551: Clinical Trial Endpoints (Oncological Indications)
  • Table 6.5 MEDI-551: Clinical Trial Endpoints (Non-Oncological Indications)
  • Table 6.6 MEDI-551: Dosage Regimen
  • Table 6.7 MedImmune: Antibody Based Pipeline
  • Table 6.8 MOR208: Clinical Development
  • Table 6.9 MOR208: Clinical Trial Endpoints
  • Table 6.10 MOR208: Dosage Regimen
  • Table 6.11 MorphoSys: Antibody Based Pipeline
  • Table 6.12 Drugs Based on POTELLIGENT® Technology
  • Table 6.13 Drugs Based on XmAb® Antibody Technology
  • Table 7.1 CD19 Targeted Bispecific Antibodies: Pipeline Molecules and Current Status of Development
  • Table 7.2 Blinatumomab: Orphan Drug Designations
  • Table 7.3 Blinatumomab: Clinical Development
  • Table 7.4 Blinatumomab: Clinical Trial Endpoints (Relapsed/ Refractory ALL)
  • Table 7.5 Blinatumomab: Clinical Trial Endpoints (Minimal Residual Disease of B-ALL)
  • Table 7.6 Blinatumomab: Clinical Trial Endpoints (Relapsed/ Refractory B-ALL)
  • Table 7.7 Blinatumomab: Clinical Trial Endpoints (Relapsed/ Refractory DLBCL, NHL and Untreated ALL)
  • Table 7.8 Amgen: Bispecific Antibody Pipeline
  • Table 7.9 Drugs Based on BiTE® Technology
  • Table 7.10 Drugs Based on DART® Technology
  • Table 7.11 Drugs Based on TandAb Technology
  • Table 8.1 Commonly Used Cytotoxins for ADC Therapeutics
  • Table 8.2 OEL Bands, SafeBridge Consultants
  • Table 8.3 CD19 Targeted ADC: Pipeline Molecules and Current Status of Development
  • Table 8.4 Coltuximab Ravtansine: Clinical Development
  • Table 8.5 Coltuximab Ravtansine: Clinical Trial Endpoints
  • Table 8.6 Coltuximab Ravtansine: Dosage Regimen
  • Table 8.7 ImmunoGen: ADC Pipeline
  • Table 8.8 Denintuzumab Mafodotin: Clinical Development
  • Table 8.9 Denintuzumab Mafodotin: Clinical Trial Endpoints
  • Table 8.10 Denintuzumab Mafodotin: Dosage Regimen
  • Table 8.11 Seattle Genetics: ADC Pipeline
  • Table 9.1 Comparison of Hodgkin's and Non-Hodgkin Lymphoma
  • Table 9.2 Leukemia: Marketed Targeted Therapeutics
  • Table 9.3 Lymphoma: Marketed Targeted Therapeutics
  • Table 9.4 Targets under Investigational Trials for Engineered Antibodies: Hematological Cancer
  • Table 9.5 Targets under Investigational Trials for Bispecific Antibodies: Hematological Cancer
  • Table 9.6 Targets under Investigational Trials for ADC: Hematological Cancer
  • Table 9.7 Targets under Investigational Trials for CAR-T: Hematological Cancer
  • Table 10.1 Anti-CD19 Therapeutics: Market Potential of Candidates
  • Table 10.2 BLINCYTO®: Target Patient Population
  • Table 10.3 CTL019: Target Patient Population
  • Table 10.4 KTE-C19: Target Patient Population
  • Table 10.5 JCAR015: Target Patient Population
  • Table 10.6 Coltuximab Ravtansine: Target Patient Population
  • Table 10.7 MEDI-551: Target Patient Population
  • Table 10.8 MOR208: Target Patient Population
  • Table 10.9 XmAb®5871: Target Patient Population
  • Table 10.10 SGN-CD19A: Target Patient Population
  • Table 13.1 Approved Antibody Therapeutics: Distribution by Year of Approval
  • Table 13.2 CD19 Therapeutics Pipeline: Distribution by Phase of Development (Clinical/ Preclinical)
  • Table 13.3 CD19 Therapeutics Pipeline: Distribution by Phase of Development (Phase III, Phase II, Phase I, Preclinical)
  • Table 13.4 CD19 Therapeutics Pipeline: Distribution by Indication
  • Table 13.5 CD19 Therapeutics Pipeline: Distribution Type of NHL
  • Table 13.6 CD19 Therapeutics Pipeline: Distribution by Type of Molecule
  • Table 13.7 CD19 Therapeutics Pipeline: Distribution by Type of Developer
  • Table 13.8 CD19 Therapeutics Pipeline: Active Players in the Industry
  • Table 13.9 Novartis: Revenue, 2010- 2015 (USD Billion)
  • Table 13.10 Novartis: Sales by Operating Segments, 2015 (USD Billion)
  • Table 13.11 Juno Therapeutics: VC Funding Instances (USD Million)
  • Table 13.12 Kite Pharma: VC Funding Instances (USD Million)
  • Table 13.13 MorphoSys: Revenue, 2011- Q3, 2015 (EUR Million)
  • Table 13.14 Amgen: Revenues, 2010 - 2015 (USD Billion)
  • Table 13.15 ImmunoGen: Revenues, 2011 - H1 2016 (USD Million)
  • Table 13.16 Seattle Genetics: Revenues, 2010-Q3, 2015 (USD Million)
  • Table 13.17 Overall CD19 Based Therapeutics Market, 2016-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Billion)
  • Table 13.18 Evolution of CD19 Based Therapeutics Market: 2020, 2025 and 2030(Base Scenario, USD Billion)
  • Table 13.19 BLINCYTO®: Sales Forecast, 2016-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 13.20 CTL019 Sales Forecast, 2017-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 13.21 KTE-C19 Sales Forecast, 2018-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 13.22 JCAR015 Sales Forecast, 2018-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 13.23 Coltuximab Ravtansine: Sales Forecast, 2019-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 13.24 MEDI-551: Sales Forecast, 2020-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 13.25 MOR208: Sales Forecast, 2020-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 13.26 XmAb5871: Sales Forecast, 2021-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 13.27 SGN-CD19A: Sales Forecast, 2024-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 13.28 CD19 Therapeutics: Distribution by Hematological Malignancies
  • Table 13.29 CD19 Therapeutics Market Forecast: Conservative, Base and Optimistic Scenarios, 2016, 2023 and 2030 (USD Billion)

Listed Companies

The following companies have been mentioned in this report.

  • 1. AbDSerotec
  • 2. Amphivena
  • 3. ADC Therapeutics
  • 4. Advaxis
  • 5. AFA Försäkring AB
  • 6. Affimed
  • 7. Agensys
  • 8. AgonOx
  • 9. AIMM Therapeutics
  • 10. Alexion
  • 11. Amgen
  • 12. arGEN-X
  • 13. Astellas Pharma
  • 14. AstraZeneca
  • 15. Autolus
  • 16. Bayer Healthcare
  • 17. Baylor College of Medicine
  • 18. Beijing Doing Biomedical Co
  • 19. Bellicum Pharmaceuticals
  • 20. Bio-Rad
  • 21. Biotest
  • 22. BioWa
  • 23. Bluebird Bio
  • 24. BoehringerIngelheim
  • 25. Cancer Research UK
  • 26. Cantargia
  • 27. Celgene
  • 28. Cellectis
  • 29. Cellular Biomedicine Group
  • 30. Cephalon
  • 31. Center for Cell and Gene Therapy
  • 32. Chinese PLA General Hospital
  • 33. City of Hope Medical Center
  • 34. CSL Limited
  • 35. Daiichi Sankyo
  • 36. Dana-Farber Cancer Institute
  • 37. Dendreon Corporation
  • 38. Dr Reddy's Laboratories
  • 39. European Medical Agency
  • 40. First Hospital of Jilin University
  • 41. FivePrime Therapeutics
  • 42. Formula Pharmaceuticals
  • 43. Fred Hutchinson Cancer Research Center
  • 44. Fuda Cancer Hospital
  • 45. Galapagos
  • 46. Genentech
  • 47. Gilead Sciences
  • 48. GSK
  • 49. Hospital to Academy of Military Medical Sciences
  • 50. HumabsBioMed
  • 51. Human Genome Sciences
  • 52. Immatics
  • 53. ImmunoCellular Therapeutics
  • 54. ImmunoCore
  • 55. ImmunoGen
  • 56. Immunomedics
  • 57. Incyte Corporation
  • 58. Intrexon Corporation
  • 59. Janssen
  • 60. Jichi Medical University
  • 61. Juno Therapeutics
  • 62. Kalibios
  • 63. Karolinska University Hospital
  • 64. Kite Pharma
  • 65. Kyowa Hakko Kirin
  • 66. Lonza
  • 67. M.D Anderson Cancer Center
  • 68. Max Delbrück Center for Molecular Medicine in the Helmholtz Association
  • 69. Medarex (acquired by BMS)
  • 70. MedImmune
  • 71. Memorial Sloan Kettering Cancer Center
  • 72. Merck
  • 73. Merck KGaA
  • 74. Merck Serono
  • 75. Mereo
  • 76. Mirati Therapeutics
  • 77. MorphoSys
  • 78. National Cancer Institute
  • 79. National Institute of Allergy and Infectious Diseases
  • 80. National Institute of Health
  • 81. NKT Therapeutics
  • 82. Novartis
  • 83. NovImmune
  • 84. Novo Nordisk
  • 85. Ohio State University
  • 86. OncoMed
  • 87. OncoTherapy Science
  • 88. Otsuka Pharmaceuticals
  • 89. Oxford BioMedica
  • 90. Oxis Biotech
  • 91. Oxford BioTherapeutics
  • 92. Peking University
  • 93. Pfizer
  • 94. Roche
  • 95. Sanofi Aventis
  • 96. Seattle Children Hospital
  • 97. Seattle Genetics
  • 98. Servier
  • 99. Shanghai GeneChem Co., Ltd.
  • 100. Shanghai Tongji Hospital
  • 101. Shenzhen Second People's Hospital
  • 102. Sidney Kimmel Comprehensive Research Center
  • 103. Spirogen
  • 104. Southwest Hospital
  • 105. Swedish Cancer Society
  • 106. Takara Bio
  • 107. Takeda
  • 108. Teva Pharmaceuticals
  • 109. Texas Children's Hospital
  • 110. The Methodist Hospital System
  • 111. Theravectys
  • 112. UCB
  • 113. University College, London
  • 114. University of California
  • 115. University of Florida
  • 116. University of Pennsylvania
  • 117. Uppsala University
  • 118. Uppsala University Hospital
  • 119. US Food and Drug Administration
  • 120. Ventana
  • 121. Xencor
  • 122. Xinqiao Hospital of Chongqing
  • 123. Ziopharm
  • 124. Zymeworks
Back to Top